We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > Ilaris

News List

FDA Approves First Treatment for Adult Onset Still’s Disease americanpharmaceuticalreview
June 28, 2020
The U.S. Food and Drug Administration (FDA) approved Ilaris (canakinumab) injection for the treatment of Active Still’s disease, including Adult-Onset Still’s Disease (AOSD).
US FDA approves Novartis’s Ilaris for Active Still’s disease treatment expresspharma
June 18, 2020
Ilaris was previously approved for Systemic Juvenile Idiopathic Arthritis (SJIA) in patients aged 2 years and older.
Novartis’ ‘life-changing’ Ilaris set for NHS funding pharmatimes
March 06, 2020
The NHS has revealed plans to fund Novartis’ Ilaris (canakinumab), for people with rare conditions causing repeated bouts of fever, joint pains and swelling.